.: ORİJİNAL ARAŞTIRMA
Evaluation of Hematological and Inflammatory Biomarkers in Patients Receiving Omalizumab Treatment in Chronic Urticaria
Kronik Ürtikerde Omalizumab Tedavisi Alan Hastalarda Hematolojik ve İnflamatuar Biyobelirteçlerin Değerlendirilmesi
Turkiye Klinikleri J Dermatol. 2021;31(1):28-35
doi: 10.5336/dermato.2021-81209
Makale Dili: EN
Tam Metin
ABSTRACT
Objective: This study aims to evaluate the effects of omalizumab on hematological parameters and inflammation biomarkers in patients diagnosed with chronic spontaneous urticaria (CSU). Material and Methods: The records of 109 (76 women and 33 men) patients, who were treated with omalizumab with the diagnosis of CSU were retrospectively examined. In addition, the pre-treatment and postomalizumab treatment periods were evaluated in CSU patients by comparing hematological, inflammatory and biochemical parameters. The data of these patients were compared to a healthy control group with similar characteristics such as age and gender. Results: C-reactive protein (CRP), neutrophil (NEU), and monocyte values were significantly higher in patients with CSU, while basophil values in control individuals. The comparison of the measurements of the patients before and after omalizumab treatment revealed a significant reduction in CRP, white blood cell (WBC), NEU, and platelet (PLT) levels. WBC, NEU, and eosinophil levels were found to be significantly reduced in responders compared to non-responders to treatment. Conclusion: The evaluation of CRP, NEU, PLT levels are found to be important to show the activity of the disease in CSU. We think that these inflammatory markers are important in the follow-up of CSU and omalizumab treatment. We think that these inflammatory markers are important in the follow-up of CSU and omalizumab treatment. Our results will contribute to the medical literature to establish both the mechanism of action of omalizumab and the parameters used in the follow-up of omalizumab therapy in patients with CSU.
Keywords: Omalizumab; chronic urticaria; inflammation
Objective: This study aims to evaluate the effects of omalizumab on hematological parameters and inflammation biomarkers in patients diagnosed with chronic spontaneous urticaria (CSU). Material and Methods: The records of 109 (76 women and 33 men) patients, who were treated with omalizumab with the diagnosis of CSU were retrospectively examined. In addition, the pre-treatment and postomalizumab treatment periods were evaluated in CSU patients by comparing hematological, inflammatory and biochemical parameters. The data of these patients were compared to a healthy control group with similar characteristics such as age and gender. Results: C-reactive protein (CRP), neutrophil (NEU), and monocyte values were significantly higher in patients with CSU, while basophil values in control individuals. The comparison of the measurements of the patients before and after omalizumab treatment revealed a significant reduction in CRP, white blood cell (WBC), NEU, and platelet (PLT) levels. WBC, NEU, and eosinophil levels were found to be significantly reduced in responders compared to non-responders to treatment. Conclusion: The evaluation of CRP, NEU, PLT levels are found to be important to show the activity of the disease in CSU. We think that these inflammatory markers are important in the follow-up of CSU and omalizumab treatment. We think that these inflammatory markers are important in the follow-up of CSU and omalizumab treatment. Our results will contribute to the medical literature to establish both the mechanism of action of omalizumab and the parameters used in the follow-up of omalizumab therapy in patients with CSU.
Keywords: Omalizumab; chronic urticaria; inflammation
ÖZET
Amaç: Bu çalışmada, kronik spontan ürtiker (KSÜ) tanılı hastalarda omalizumabın hematolojik parametreler ve inflamasyon biyobelirteçleri üzerine olan etkilerinin değerlendirmesi amaçlanmaktadır. Gereç ve Yöntemler: KSÜ tanısıyla omalizumab ile tedavi edilmiş 109 (76 kadın, 33 erkek) hastanın hastane kayıtları retrospektif olarak incelendi. Ayrıca hastalarda tedavi öncesi ve omalizumab tedavisi sonrası dönemde hematolojik, inflamatuar ve biyokimyasal parametreler karşılaştırılarak değerlendirildi. Bu hastaların verileri yaş ve cinsiyet gibi benzer özelliklere sahip sağlıklı kontrol grubu ile karşılaştırıldı. Bulgular: C-reaktif protein (CRP), nötrofil (NEU), monosit değerleri KSÜ'lü hastalarda ve bazofil değeri ise kontrol bireylerinde anlamlı düzeyde daha yüksek olduğu görüldü. Hastalarda omalizumab tedavisi öncesi ve sonrası ölçümleri karşılaştırıldığında CRP, beyaz kan hücresi [white blood cell (WBC)], NEU ve platelet (PLT) düzeylerinde anlamlı azalma tespit edildi. Tedaviye yanıt veren hastalarda WBC, NEU, EOS düzeyleri, yanıt vermeyenlerle karşılaştırıldığında anlamlı düzeyde azaldığı bulundu. Sonuç: KSÜ'de hastalığın aktivitesini göstermek için CRP, NEU, PLT düzeylerinin değerlendirilmesinin önemli olduğu bulundu. KSÜ ve omalizumab tedavisinin takibinde bu inflamatuar belirteçlerinin önemli olduğunu düşünmekteyiz. Sonuçlarımız, KSÜ hastalarında hem omalizumabın etki mekanizmasını hem de omalizumab tedavisinde takipte kullanılan parametreleri oluşturmak için tıbbi literatüre katkıda bulunacaktır.
Anahtar Kelimeler: Omalizumab; kronik ürtiker; inflamasyon
Amaç: Bu çalışmada, kronik spontan ürtiker (KSÜ) tanılı hastalarda omalizumabın hematolojik parametreler ve inflamasyon biyobelirteçleri üzerine olan etkilerinin değerlendirmesi amaçlanmaktadır. Gereç ve Yöntemler: KSÜ tanısıyla omalizumab ile tedavi edilmiş 109 (76 kadın, 33 erkek) hastanın hastane kayıtları retrospektif olarak incelendi. Ayrıca hastalarda tedavi öncesi ve omalizumab tedavisi sonrası dönemde hematolojik, inflamatuar ve biyokimyasal parametreler karşılaştırılarak değerlendirildi. Bu hastaların verileri yaş ve cinsiyet gibi benzer özelliklere sahip sağlıklı kontrol grubu ile karşılaştırıldı. Bulgular: C-reaktif protein (CRP), nötrofil (NEU), monosit değerleri KSÜ'lü hastalarda ve bazofil değeri ise kontrol bireylerinde anlamlı düzeyde daha yüksek olduğu görüldü. Hastalarda omalizumab tedavisi öncesi ve sonrası ölçümleri karşılaştırıldığında CRP, beyaz kan hücresi [white blood cell (WBC)], NEU ve platelet (PLT) düzeylerinde anlamlı azalma tespit edildi. Tedaviye yanıt veren hastalarda WBC, NEU, EOS düzeyleri, yanıt vermeyenlerle karşılaştırıldığında anlamlı düzeyde azaldığı bulundu. Sonuç: KSÜ'de hastalığın aktivitesini göstermek için CRP, NEU, PLT düzeylerinin değerlendirilmesinin önemli olduğu bulundu. KSÜ ve omalizumab tedavisinin takibinde bu inflamatuar belirteçlerinin önemli olduğunu düşünmekteyiz. Sonuçlarımız, KSÜ hastalarında hem omalizumabın etki mekanizmasını hem de omalizumab tedavisinde takipte kullanılan parametreleri oluşturmak için tıbbi literatüre katkıda bulunacaktır.
Anahtar Kelimeler: Omalizumab; kronik ürtiker; inflamasyon
REFERANSLAR:
- Taşkın B, Eriş Eken Z, Alper S. [The diagnosis and treatment approches in chronic spontaneous urticaria]. Turkiye Klinikleri J Dermatol-Special Topics. 2015;8(1):20-5.[Link]
- Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Giménez-Arnau A, et al; Dermatology Section of the European Academy of Allergology and Clinical Immunology; Global Allergy and Asthma European Network; European Dermatology Forum; World Allergy Organization. EAACI/GA(2) LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy. 2009;64(10):1417-26.[Crossref] [PubMed]
- Młynek A, Maurer M, Zalewska A. Update on chronic urticaria: focusing on mechanisms. Curr Opin Allergy Clin Immunol. 2008;8(5):433-7.[Crossref] [PubMed]
- Asero R, Tedeschi A, Riboldi P, Cugno M. Plasma of patients with chronic urticaria shows signs of thrombin generation, and its intradermal injection causes wheal-and-flare reactions much more frequently than autologous serum. J Allergy Clin Immunol. 2006;117(5):1113-7.[Crossref] [PubMed]
- Zhu H, Liang B, Li R, Li J, Lin L, Ma S, et al. Activation of coagulation, anti-coagulation, fibrinolysis and the complement system in patients with urticaria. Asian Pac J Allergy Immunol. 2013;31(1):43-50.[PubMed]
- Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW, et al; European Academy of Allergy and Clinical Immunology; Global Allergy and Asthma European Network; European Dermatology Forum; World Allergy Organization. The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014;69(7):868-87.[PubMed]
- Kaplan AP, Giménez-Arnau AM, Saini SS. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria. Allergy. 2017;72(4):519-33.[Crossref] [PubMed] [PMC]
- Maurer M, Rosén K, Hsieh HJ, Saini S, Grattan C, Gimenéz-Arnau A, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368(10):924-35. Erratum in: N Engl J Med. 2013;368(24):2340-1.[Crossref] [PubMed]
- Saini SS, Bindslev-Jensen C, Maurer M, Grob JJ, Bülbül Baskan E, Bradley MS, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol. 2015;135(1):67-75. Erratum in: J Invest Dermatol. 2015;135(3):925.[Crossref] [PubMed] [PMC]
- Altrichter S, Hawro T, Hänel K, Czaja K, Lüscher B, Maurer M, Baron J. Successful omalizumab treatment in chronic spontaneous urticaria is associated with lowering of serum IL‐31 levels. Journal of the European Academy of Dermatology and Venereology. 2016;30(3)454-5.[Crossref] [PubMed]
- Kasperska-Zajac A, Sztylc J, Machura E, Jop G. Plasma IL-6 concentration correlates with clinical disease activity and serum C-reactive protein concentration in chronic urticaria patients. Clin Exp Allergy. 2011;41(10):1386-91.[Crossref] [PubMed]
- Kasperska-Zajac A, Grzanka A, Machura E, Misiolek M, Mazur B, Jochem J. Increased serum complement C3 and C4 concentrations and their relation to severity of chronic spontaneous urticaria and CRP concentration. J Inflamm (Lond). 2013;10(1):22.[Crossref] [PubMed] [PMC]
- Deza G, Ricketti PA, Giménez-Arnau AM, Casale TB. Emerging Biomarkers and Therapeutic Pipelines for Chronic Spontaneous Urticaria. J Allergy Clin Immunol Pract. 2018;6(4):1108-17.[Crossref] [PubMed]
- Vagdatli E, Gounari E, Lazaridou E, Katsibourlia E, Tsikopoulou F, Labrianou I. Platelet distribution width: a simple, practical and specific marker of activation of coagulation. Hippokratia. 2010;14(1):28-32.[PubMed] [PMC]
- Kasperska-Zając A, Grzanka A, Jarzab J, Misiołek M, Wyszyńska-Chłap M, Kasperski J, et al. The association between platelet count and acute phase response in chronic spontaneous urticaria. Biomed Res Int. 2014;2014:650913.[Crossref] [PubMed] [PMC]
- Göncü EK, Aktan Ş, Atakan N, Başkan EB, Erdem T, Koca R, et al. The Turkish guideline for the diagnosis and management of urticaria-2016. Turkderm. 2016;50;82-98.[Crossref]
- Gasparyan AY, Ayvazyan L, Mikhailidis DP, Kitas GD. Mean platelet volume: a link between thrombosis and inflammation? Curr Pharm Des. 2011;17(1):47-58.[Crossref] [PubMed]
- Ihara A, Kawamoto T, Matsumoto K, Shouno S, Morimoto T, Noma Y. Relationship between hemostatic factors and the platelet index in patients with ischemic heart disease. Pathophysiol Haemost Thromb. 2006;35(5):388-91.[Crossref] [PubMed]
- Prajapati JH, Sahoo S, Nikam T, Shah KH, Maheriya B, Parmar M. Association of high density lipoprotein with platelet to lymphocyte and neutrophil to lymphocyte ratios in coronary artery disease patients. J Lipids. 2014;2014:686791.[Crossref] [PubMed] [PMC]
- Avci A, Avci D, Erden F, Ragip E, Cetinkaya A, Ozyurt K, et al. Can we use the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and mean platelet volume values for the diagnosis of anterior uveitis in patients with Behcet's disease? Ther Clin Risk Manag. 2017;13:881-6.[Crossref] [PubMed] [PMC]
- Magen E, Mishal J, Zeldin Y, Feldman V, Kidon M, Schlesinger M, et al. Increased mean platelet volume and C-reactive protein levels in patients with chronic urticaria with a positive autologous serum skin test. Am J Med Sci. 2010;339(6):504-8.[Crossref] [PubMed]
- Djordjevic D, Rondovic G, Surbatovic M, Stanojevic I, Udovicic I, Andjelic T, et al. Neutrophil-to-Lymphocyte Ratio, Monocyte-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Mean Platelet Volume-to-Platelet Count Ratio as Biomarkers in Critically Ill and Injured Patients: Which Ratio to Choose to Predict Outcome and Nature of Bacteremia? Mediators Inflamm. 2018;2018:3758068.[Crossref] [PubMed] [PMC]
- Chang TW, Chen C, Lin CJ, Metz M, Church MK, Maurer M. The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria. J Allergy Clin Immunol. 2015;135(2):337-42.[Crossref] [PubMed]
- Zuberbier T, Aberer W, Asero R, Abdul Latiff AH, Baker D, Ballmer-Weber B, et al; Endorsed by the following societies: AAAAI, AAD, AAIITO, ACAAI, AEDV, APAAACI, ASBAI, ASCIA, BAD, BSACI, CDA, CMICA, CSACI, DDG, DDS, DGAKI, DSA, DST, EAACI, EIAS, EDF, EMBRN, ESCD, GA²LEN, IAACI, IADVL, JDA, NVvA, MSAI, ÖGDV, PSA, RAACI, SBD, SFD, SGAI, SGDV, SIAAIC, SIDeMaST, SPDV, TSD, UNBB, UNEV and WAO. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73(7):1393-414.[Crossref] [PubMed]
- Jörg L, Pecaric-Petkovic T, Reichenbach S, Coslovsky M, Stalder O, Pichler W, et al. Double-blind placebo-controlled trial of the effect of omalizumab on basophils in chronic urticaria patients. Clin Exp Allergy. 2018;48(2):196-204.[Crossref] [PubMed]
- Puxeddu I, Pratesi F, Ribatti D, Migliorini P. Mediators of Inflammation and Angiogenesis in Chronic Spontaneous Urticaria: Are They Potential Biomarkers of the Disease? Mediators Inflamm. 2017;2017:4123694.[Crossref] [PubMed] [PMC]
- Kaplan AP, Greaves M. Pathogenesis of chronic urticaria. Clin Exp Allergy. 2009;39(6):777-87.[Crossref] [PubMed]
- Folci M, Heffler E, Canonica GW, Furlan R, Brunetta E. Cutting Edge: Biomarkers for Chronic Spontaneous Urticaria. J Immunol Res. 2018;2018:5615109.[Crossref] [PubMed] [PMC]
- Akdogan N, Demirel Ogut N, Dogan S, Atakan N. Long-term effects of omalizumab on peripheral blood cells and C-reactive protein levels in patients with chronic spontaneous urticaria. Dermatol Ther. 2019;32(4):e12966.[Crossref] [PubMed]
- Acer E, Kaya Erdogan H, Yüksel Çanakçı N, Saracoglu ZN. The effect of omalizumab on hematological and inflammatory parameters in patients with chronic spontaneous urticaria. Cutan Ocul Toxicol. 2019;38(1):5-8.[Crossref] [PubMed]
- Maouia A, Youssef M, Leban N, Ben Chibani J, Helal A. N, Kassab A. CRP relevance in clinical assessment of chronic spontaneous urticaria Tunisian patients. Cutaneous and Ocular Toxicology. 2017;36(4):387-92.[Crossref] [PubMed]
- Kolkhir P, Altrichter S, Hawro T, Maurer M. C-reactive protein is linked to disease activity, impact, and response to treatment in patients with chronic spontaneous urticaria. Allergy. 2018;73(4):940-8.[Crossref] [PubMed]
- Asero R, Cugno M, Tedeschi A. Eosinophils in chronic urticaria: supporting or leading actors? World Allergy Organ J. 2009;2(9):213-7.[Crossref] [PubMed] [PMC]
- Tamer F. Omalizumab does not lead to a distinct alteration in hematological parameters and complete blood count-derived inflammation biomarkers except for basophil count. Cutan Ocul Toxicol. 2020;39(3):229-32.[Crossref] [PubMed]
- Ertaş R, Özyurt K, Karakükçü Ç, Akkuş MR, Özlü E, Avcı A, et al. Evaluation of platelet parameters and neutrophil/lymphocyte ratio during omalizumab treatment in patients with severe chronic spontaneous urticaria. Turk J Med Sci. 2018;48(6):1255-62.[Crossref] [PubMed]
.: İşlem Listesi